>>Biomarker Discovery Firm Biospect Raises $27M in Financing, Appoints CEO
By a GenomeWeb staff reporter
NEW YORK, Oct. 21 (GenomeWeb News) - Biospect, a South San Francisco, Calif.-based startup developing systems for detecting biomarker patterns, today said it has received more than $27 million in equity financing from four venture capital firms: Advent Venture Partners, Prospect Venture Partners, Venrock Associates, and Versant Ventures.
In addition, the company said that it has appointed Deborah Neff as president and CEO. Neff, who most recently held the position of worldwide president of BD Biosciences, will also serve on Biospect's board of directors.
Jim Tananbaum, chairman of Biospect and managing partner of Prospect Venture Partners, said the company plans to use the funding to commercialize its biomarker platform, which consists of proprietary separation, detection, and informatics technologies to detect patterns that characterize distinct biological states.<<
Cheers, Tuck |
